Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2017-07-06 Regulatory Filings
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys Celebrates 25th Anniversary (news with additional features)
Regulatory Filings Classification · 100% confidence The document is a press release dated July 6, 2017, announcing that MorphoSys AG is celebrating its 25th company anniversary. It discusses the company's history, achievements, and future outlook, including a potential drug approval (guselkumab). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a general corporate announcement regarding a milestone event, which fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate news item, or potentially a general 'Miscellaneous' category if one existed. Given the provided options, 'RNS' (Regulatory Filings / General regulatory announcements and fallback category) is the most appropriate classification for a non-standard, non-financial-period-specific corporate news release.
2017-07-06 English
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'MorphoSys AG: Release according to Article 26a of the WpHG' and specifically announces the 'Publication of total number of voting rights' as of '30.06.2017'. It details a 'Type of capital measure' as 'Conditional capital increase' and states the 'New total number of voting rights: 29.326.110'. This type of announcement, which reports on changes to the total number of voting rights, aligns most closely with the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), as it is an official notification related to shareholder voting power/rights, even if it stems from a capital measure. It is not a full financial report (10-K, IR) or a general regulatory filing (RNS), but a specific disclosure regarding voting rights.
2017-06-30 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section header 'DGAP-DD: MorphoSys AG english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities...'. This content directly relates to reporting personal share transactions by company directors and executives (insider trades). This matches the definition for Director's Dealing (DIRS). The document length is short, but the content is the actual disclosure, not an announcement of a report.
2017-06-28 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly contains the header "Voting Rights Announcements" and details the acquisition/disposal of shares with voting rights by a major shareholder (Templeton Funds Trust) in MorphoSys AG, referencing German Securities Trading Act (WpHG) sections (Article 26, Section 1, Sec. 21, Sec. 22, Sec. 25). This directly corresponds to the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA), which covers notifications of changes in significant share ownership thresholds crossing.
2017-06-21 English
MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma at ASCO 2017 (news with additional features)
Regulatory Filings Classification · 100% confidence The document is a press release dated June 5, 2017, announcing updated clinical data for the anti-CD38 antibody MOR202 presented at the ASCO 2017 Annual Meeting. It details safety, efficacy, patient cohorts, and future presentation plans. This content is characteristic of an announcement regarding clinical trial progress and scientific presentation, which is typically disseminated via an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement of results/data presentation rather than a comprehensive periodic financial report (like 10-K or IR), and it is not a transcript (CT) or a formal investor presentation document (IP), the most fitting category for a time-sensitive announcement of key operational/clinical results is 'Earnings Release' (ER), as these often include non-financial operational highlights like clinical data updates, especially when disseminated via news services like DGAP/EQS. Given the context of clinical data presentation, it is a form of operational update that precedes a full financial report.
2017-06-05 English
MorphoSys Starts Phase 3 Trial of MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL (news with additional features)
Regulatory Filings Classification · 99% confidence The document is a news release dated June 2, 2017, announcing that MorphoSys AG has started the Phase 3 trial of its drug candidate MOR208. It details the study design (B-MIND trial), patient population, and collaboration milestones. This type of announcement, focusing on clinical trial progression and regulatory/development milestones, is typically classified as a general corporate announcement or news release. Since it is not a formal financial report (like 10-K or IR), a specific management discussion (MDA), or an earnings release (ER), and it is not explicitly a proxy statement (DEF 14A) or a director's dealing (DIRS), the most appropriate general category for significant corporate development news that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for official corporate news disseminated via services like DGAP/EQS.
2017-06-02 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.